| |
Release Date
07/10/2012
Expiration Date
07/10/2013
This program has expired. CME credit is no longer available. |
|
|
| |
|
|
| |
 |
|
Ira Jacobson, MD
Weill Cornell Medical College
New York, NY |
|
| |
| |
To earn CME credits, all 3 webcasts must be completed. |
|
| |
| |
 |
|
| |
|
|
| |
| View Webcast 1 |
| - |
A 12-Week Regimen of ABT-450/r, ABT-072, +Ribavirin in TX-Naive |
| - |
12-Week Regimen of ABT-450/r+ABT-333+Ribavirin in Previous Non-Reson.. |
| - |
ELECTRON: Once Daily PSI-7977 plus RBV in HCV GT1/2/3 |
| |
|
| View Webcast 2 |
| - |
Interim Results of Sound-C2, BI201335 and BI207127, +/- Ribavirin.. |
| - |
Interim Analysis from SOUND-C2, BI201335 and BI207127 in G1 Cirrhotics |
| - |
All-Oral Combo of Daclatasvir and GS-7977, +/-Ribavirin in TX Naive |
| |
|
| View Webcast 3 |
| - |
NS5A Inhibitor Daclatasvir and NS3 Protese Inhibitor Asunaprevir |
| - |
Quad Therapy, Daclatasvir Asunaprevir & Peg IFN/Ribavirin G1 Null.. |
| - |
SVR 24 Results from EMERGE, Peg Lambda-1a VS Peg Alfa-2A in G2/3.. |
| - |
SVR 24 Result ASPIRE, IMC435 in HCV G1 Previously Treated Pts. |
| |
|
|
|
| |
|
|
| |
 |
|
| |
 |
|
| |
Jointly sponsored by The Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation. |
|
| |
|
|
| |
This activity
supported by: |
|
| |
Janssen Therapeutics
Vertex Pharmaceuticals |
|
| |
|
|
|
|
|
| Target Audience |
| This activity was developed for gastroenterologists and hepatologists and other health care providers managing patients with HCV. |
| |
| Statement of Need/Program
Overview |
| The purpose of this activity is to enhance the care of patients with Hepatitis C. |
| |
| Educational Objectives |
| At the conclusion of this initiative, participants will do the following: |
|
• |
Identify new compounds currently under investigation for the treatment of chronic hepatitis C |
| • |
Recognize the potential efficacy and safety benefits of new therapies for chronic hepatitis C currently under investigation |
| • |
Describe how new compounds might fit into the future treatment armamentarium for chronic hepatitis C |
|
| |
| Physician Accreditation
Statement |
| This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians. |
| |
| Credit Designation |
| The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
| |
| This activity is an enduring material and consists of a web activity. Successful completion is achieved by reading and viewing the material, reflecting on its implications in your practice, and completing the assessment component. |
| |
| Cost of activity |
| There is no charge for this activity. |
| |
| Faculty Disclosure Statement |
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:
Ira Jacobson, MD
Grants/ Research Support: Schering, Tibotec, Roche, Genentech, Pharmasset, Anadys, Boehringer Ingelheim, Novartis, Gilead, Vertex, GlobeImmune, Human Genome Sciences, Pfizer, Bristol Myers Squibb and Zymogenetics Consultant: Bristol Myers Squibb, Novartis, Gilead, Schering, Merck, Pfizer, Vertex, GlobeImmune, Human Genome Sciences, Boehringer Ingelheim, Pharmasset, Zymogenetics, TIbotec, Abbott, Roche, Genentech, Anadys, Sanofi-Aventis, Achillion, Glaxo Smith Kline and Biolex. Advisory Board Membership: Schering, Merck, Gilead, Bristol Myers Squibb, Novartis, Roche, Genentech Speaker Bureau for:Schering, Merck, Gilead, Bristol Meyers Squibb and Roche/Genentech.
Dr. Jacobson has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Additional content planners: In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made.
All staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
This activity is supported by an independent educational grant from Janssen Therapeutics and Vertex Pharmaceuticals. |
| |
|
